In this issue:
- ICI + chemotherapy for thoracic SMARCA4-deficient UT
- PDL1 copy number alteration as biomarker of response to ICI in NSCLC
- Age & survival trends in advanced NSCLC after introduction of ICIs
- Gefitinib + chemotherapy in untreated EGFR-mutated NSCLC with brain metastases
- Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA NSCLC
- Poor physiotherapy/exercise management in surgical lung cancer care in Australia & NZ
- AI predictions of EGFR mutation status in NSCLC
- Radiomics-based tool to improve lung cancer diagnosis
- Postoperative health-related QOL & preoperative anxiety
- Ethnic disparities in emergency presentation prior to lung cancer diagnosis in NZ
Please login below to download this issue (PDF)